Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis.

The article analyses the clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma (BCC) and solar keratosis. Photodynamic therapy (PDT) using methyl aminolaevulinate 160 mg/g cream has recently been approved in Australia for the treatment of thin or non-hyperkeratotic and non-pigmented solar keratoses on the face and scalp when other registered therapies are unacceptable. PDT is a simple, doctor-controlled procedure with an established treatment protocol and which allows multiple lesions to be treated during the same session. It is well tolerated, with predictable local phototoxic adverse events, high patient acceptance and has superior cosmetic outcome.